LCN6: A Potential Drug Target with Unique Structure and N-VHR

Target Name: LCN6

NCBI ID: G158062

LCN6

LCN6: A Potential Drug Target with Unique Structure and N-VHR

LCN6 (UNQ643) is a protein that is expressed in various tissues throughout the body, including the brain, heart, and kidneys. It is a member of the long chain non-protein-conjugated (LCN) family of proteins, which are characterized by the presence of a long terminal extension, also known as an N-terminal hypervariable region (N-VHR), in the protein sequence.

The N-VHR is a region of the protein sequence that is responsible for the binding of various small molecules, including drugs and toxins, as well as other proteins. This region can also be used to study protein-protein interactions and to identify potential drug targets.

LCN6 is of particular interest as a potential drug target due to its unique structure and the presence of the N-VHR in its sequence. The N-VHR is known to play a role in the regulation of various cellular processes, including cell adhesion, migration, and signaling pathways. It is also involved in the regulation of inflammation and stress responses.

One of the key features of LCN6 is its ability to interact with small molecules, including drugs that are known to modulate its function. For example, studies have shown thatLCN6 can interact with various inhibitors of its N-VHR, including small molecules such as methotrexate, topiramate, and camptothecins. These interactions may play a role in the regulation ofLCN6 function and could be potential drug targets.

Another potential mechanism by which LCN6 may be targeted by drugs is its role in the regulation of cellular signaling pathways.LCN6 has been shown to be involved in the regulation of various signaling pathways, including the TGF-β pathway, which is involved in cell growth, differentiation, and stress responses.

LCN6 has also been shown to play a role in the regulation of inflammation and stress responses. It is involved in the regulation of various cellular inflammatory mediators, including the production of reactive oxygen species (ROS) and the production of pro-inflammatory cytokines.

In addition to its potential role in the regulation of cellular processes, LCN6 is also of interest as a potential biomarker for a variety of diseases. For example, studies have shown that LCN6 is involved in the regulation of cellular stress responses, which may be relevant to a variety of diseases, including neurodegenerative disorders, autoimmune diseases, and chronic diseases such as diabetes and cardiovascular disease.

Overall, LCN6 is a protein that is of interest as a potential drug target due to its unique structure and the presence of its N-VHR in its sequence. The N-VHR is known to play a role in the regulation of various cellular processes, including cell adhesion, migration, and signaling pathways, and LCN6 is involved in the regulation of these processes. Additionally, LCN6 has been shown to play a role in the regulation of inflammation and stress responses, which may be relevant to a variety of diseases. Further research is needed to fully understand the role of LCN6 in these processes and to identify potential drug targets.

Protein Name: Lipocalin 6

Functions: May play a role in male fertility

The "LCN6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCN6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets